Cardiva Medical
Debt Financing in 2018
Cardiva Medical, Inc. is a medical device company based in Santa Clara, California, specializing in innovative vascular access management products that facilitate the healing process following percutaneous catheterization procedures. Founded in 2002, the company develops and markets several key products, including the VASCADE VCS, an extravascular and bioabsorbable femoral access closure system that promotes rapid hemostasis while reducing complications for patients. Additionally, Cardiva offers the Cardiva CATALYST, a manual compression assistance device that enhances coagulation and provides temporary hemostasis. The company also manufactures the VASCADE MVP, designed for multi-site venous closure in electrophysiology procedures. Cardiva Medical primarily serves physicians and cardiac centers across the United States, focusing on transforming vascular closure to benefit patients and healthcare providers.
Intuity Medical
Debt Financing in 2018
Intuity Medical, Inc. is a medical technology company specializing in blood glucose monitoring systems for diabetes management. Founded in 2002 and headquartered in Fremont, California, the company is known for its innovative POGO Automatic Blood Glucose Monitoring System. This system is the first FDA-cleared automatic, one-step blood glucose meter that integrates lancing, blood collection, and analysis into a single cartridge capable of performing ten tests. Intuity Medical aims to provide a convenient and discreet solution for patients who require regular blood glucose testing, enhancing their ability to manage their diabetes effectively. The company was previously known as Rosedale Medical, Inc. until it rebranded in June 2007.
Cardiva Medical
Venture Round in 2017
Cardiva Medical, Inc. is a medical device company based in Santa Clara, California, specializing in innovative vascular access management products that facilitate the healing process following percutaneous catheterization procedures. Founded in 2002, the company develops and markets several key products, including the VASCADE VCS, an extravascular and bioabsorbable femoral access closure system that promotes rapid hemostasis while reducing complications for patients. Additionally, Cardiva offers the Cardiva CATALYST, a manual compression assistance device that enhances coagulation and provides temporary hemostasis. The company also manufactures the VASCADE MVP, designed for multi-site venous closure in electrophysiology procedures. Cardiva Medical primarily serves physicians and cardiac centers across the United States, focusing on transforming vascular closure to benefit patients and healthcare providers.
Intuity Medical
Venture Round in 2016
Intuity Medical, Inc. is a medical technology company specializing in blood glucose monitoring systems for diabetes management. Founded in 2002 and headquartered in Fremont, California, the company is known for its innovative POGO Automatic Blood Glucose Monitoring System. This system is the first FDA-cleared automatic, one-step blood glucose meter that integrates lancing, blood collection, and analysis into a single cartridge capable of performing ten tests. Intuity Medical aims to provide a convenient and discreet solution for patients who require regular blood glucose testing, enhancing their ability to manage their diabetes effectively. The company was previously known as Rosedale Medical, Inc. until it rebranded in June 2007.
Apollo Endosurgery
Convertible Note in 2015
Apollo Endosurgery, Inc. is a medical technology company based in Austin, Texas, specializing in the design, development, and commercialization of innovative medical devices for gastrointestinal health. Founded in 2005, the company focuses on advancing therapeutic endoscopy as a less invasive alternative to traditional surgical procedures, thereby reducing complication rates and overall healthcare costs. Its product portfolio includes the OverStitch and OverStitch Sx Endoscopic Suturing Systems, which enable physicians to place full-thickness sutures and secure tissue approximation through flexible endoscopy. Additionally, Apollo offers the X-Tack Endoscopic HeliX Tacking System and the Orbera Intragastric Balloon, which aids in weight management by reducing stomach capacity. The company's devices cater to gastroenterologists and bariatric surgeons, addressing various gastrointestinal conditions such as acute perforations and chronic fistulas. Apollo Endosurgery's commitment to innovation is rooted in the collaborative efforts of a distinguished group of gastroenterologists and surgeons who aimed to enhance the field of therapeutic endoscopy.
Cardiva Medical
Venture Round in 2014
Cardiva Medical, Inc. is a medical device company based in Santa Clara, California, specializing in innovative vascular access management products that facilitate the healing process following percutaneous catheterization procedures. Founded in 2002, the company develops and markets several key products, including the VASCADE VCS, an extravascular and bioabsorbable femoral access closure system that promotes rapid hemostasis while reducing complications for patients. Additionally, Cardiva offers the Cardiva CATALYST, a manual compression assistance device that enhances coagulation and provides temporary hemostasis. The company also manufactures the VASCADE MVP, designed for multi-site venous closure in electrophysiology procedures. Cardiva Medical primarily serves physicians and cardiac centers across the United States, focusing on transforming vascular closure to benefit patients and healthcare providers.
Intersect ENT
Series D in 2013
Intersect ENT, Inc. is a medical device company focused on developing innovative therapies for patients with ear, nose, and throat conditions. Founded in 2003 and headquartered in Menlo Park, California, the company specializes in drug delivery products aimed at enhancing treatment outcomes for chronic sinusitis and other related ailments. Its key offerings include the PROPEL and PROPEL mini drug-releasing implants, designed for patients undergoing sinus surgery, as well as the PROPEL Contour implant, which targets frontal and maxillary sinus ostia. Additionally, Intersect ENT provides SINUVA, a steroid-releasing implant intended for use in a physician office setting to address refractory disease. The company was previously known as Sinexus, Inc. before rebranding in 2009.
Tryton Medical
Venture Round in 2013
Tryton Medical, Inc. is a medical device company based in Durham, North Carolina, specializing in the development and manufacture of side branch stent systems designed for the treatment of coronary bifurcation lesions. Established in 2003, the company focuses on addressing cardiovascular diseases by providing innovative solutions, particularly through its flagship product, the Tryton Side Branch Stent System. This system offers a targeted approach to treating atherosclerotic lesions located in the side branches at bifurcation sites. Tryton Medical distributes its products internationally and also caters to investigational needs within the United States, demonstrating its commitment to advancing cardiovascular care in various markets, including Europe and beyond.
Mirna Therapeutics
Series C in 2012
Mirna Therapeutics, Inc. is a discovery-stage biopharmaceutical company that specializes in developing miRNA-directed therapies for human oncology. With a strong focus on research and a deep understanding of microRNA and cancer biology, Mirna is positioned to advance the emerging field of miRNA-based therapeutics. The company boasts a robust intellectual property portfolio that supports its innovative approach to cancer treatment.
Cardiva Medical
Venture Round in 2012
Cardiva Medical, Inc. is a medical device company based in Santa Clara, California, specializing in innovative vascular access management products that facilitate the healing process following percutaneous catheterization procedures. Founded in 2002, the company develops and markets several key products, including the VASCADE VCS, an extravascular and bioabsorbable femoral access closure system that promotes rapid hemostasis while reducing complications for patients. Additionally, Cardiva offers the Cardiva CATALYST, a manual compression assistance device that enhances coagulation and provides temporary hemostasis. The company also manufactures the VASCADE MVP, designed for multi-site venous closure in electrophysiology procedures. Cardiva Medical primarily serves physicians and cardiac centers across the United States, focusing on transforming vascular closure to benefit patients and healthcare providers.
Apollo Endosurgery
Series B in 2012
Apollo Endosurgery, Inc. is a medical technology company based in Austin, Texas, specializing in the design, development, and commercialization of innovative medical devices for gastrointestinal health. Founded in 2005, the company focuses on advancing therapeutic endoscopy as a less invasive alternative to traditional surgical procedures, thereby reducing complication rates and overall healthcare costs. Its product portfolio includes the OverStitch and OverStitch Sx Endoscopic Suturing Systems, which enable physicians to place full-thickness sutures and secure tissue approximation through flexible endoscopy. Additionally, Apollo offers the X-Tack Endoscopic HeliX Tacking System and the Orbera Intragastric Balloon, which aids in weight management by reducing stomach capacity. The company's devices cater to gastroenterologists and bariatric surgeons, addressing various gastrointestinal conditions such as acute perforations and chronic fistulas. Apollo Endosurgery's commitment to innovation is rooted in the collaborative efforts of a distinguished group of gastroenterologists and surgeons who aimed to enhance the field of therapeutic endoscopy.
Cardiva Medical
Venture Round in 2011
Cardiva Medical, Inc. is a medical device company based in Santa Clara, California, specializing in innovative vascular access management products that facilitate the healing process following percutaneous catheterization procedures. Founded in 2002, the company develops and markets several key products, including the VASCADE VCS, an extravascular and bioabsorbable femoral access closure system that promotes rapid hemostasis while reducing complications for patients. Additionally, Cardiva offers the Cardiva CATALYST, a manual compression assistance device that enhances coagulation and provides temporary hemostasis. The company also manufactures the VASCADE MVP, designed for multi-site venous closure in electrophysiology procedures. Cardiva Medical primarily serves physicians and cardiac centers across the United States, focusing on transforming vascular closure to benefit patients and healthcare providers.
Intersect ENT
Series C in 2010
Intersect ENT, Inc. is a medical device company focused on developing innovative therapies for patients with ear, nose, and throat conditions. Founded in 2003 and headquartered in Menlo Park, California, the company specializes in drug delivery products aimed at enhancing treatment outcomes for chronic sinusitis and other related ailments. Its key offerings include the PROPEL and PROPEL mini drug-releasing implants, designed for patients undergoing sinus surgery, as well as the PROPEL Contour implant, which targets frontal and maxillary sinus ostia. Additionally, Intersect ENT provides SINUVA, a steroid-releasing implant intended for use in a physician office setting to address refractory disease. The company was previously known as Sinexus, Inc. before rebranding in 2009.
IDev Technologies
Series D in 2010
IDEV Technologies is an emerging growth medical device company that specializes in the development of innovative products for endovascular and interventional applications, particularly within interventional radiology, gastroenterology, vascular surgery, and cardiology. The company markets its flagship product, SUPERA, a self-expanding nitinol stent designed with a patented interwoven structure that enhances flexibility, radial strength, and resistance to kinking and crushing compared to competing stents. SUPERA is approved for treating biliary strictures in the United States and is currently undergoing clinical evaluation in the SUPERB IDE trial to assess its safety and efficacy for use in the superficial femoral artery.
Tryton Medical
Series D in 2010
Tryton Medical, Inc. is a medical device company based in Durham, North Carolina, specializing in the development and manufacture of side branch stent systems designed for the treatment of coronary bifurcation lesions. Established in 2003, the company focuses on addressing cardiovascular diseases by providing innovative solutions, particularly through its flagship product, the Tryton Side Branch Stent System. This system offers a targeted approach to treating atherosclerotic lesions located in the side branches at bifurcation sites. Tryton Medical distributes its products internationally and also caters to investigational needs within the United States, demonstrating its commitment to advancing cardiovascular care in various markets, including Europe and beyond.
Ortho Kinematics
Series A in 2010
Ortho Kinematics, Inc. is a healthcare diagnostics company based in Austin, Texas, specializing in spine imaging informatics. Founded in 2006, the company develops innovative diagnostic technology solutions for assessing spinal health. Its flagship product, the KineGraph Vertebral Motion Analyzer, employs fluoroscopy to capture spine motion and produce detailed patient-specific graphs that assist clinicians in diagnosing spinal instability and related conditions. In addition to its diagnostic devices, Ortho Kinematics offers comprehensive spine diagnostic imaging services through its imaging center in Austin, providing valuable information to healthcare professionals for the effective treatment of back and neck pain.
Ortho Kinematics
Venture Round in 2009
Ortho Kinematics, Inc. is a healthcare diagnostics company based in Austin, Texas, specializing in spine imaging informatics. Founded in 2006, the company develops innovative diagnostic technology solutions for assessing spinal health. Its flagship product, the KineGraph Vertebral Motion Analyzer, employs fluoroscopy to capture spine motion and produce detailed patient-specific graphs that assist clinicians in diagnosing spinal instability and related conditions. In addition to its diagnostic devices, Ortho Kinematics offers comprehensive spine diagnostic imaging services through its imaging center in Austin, providing valuable information to healthcare professionals for the effective treatment of back and neck pain.
Alereon
Venture Round in 2008
Alereon, Inc. is a fabless semiconductor company based in Austin, Texas, specializing in the development and marketing of ultra wideband (UWB) wireless chipsets. Founded in 2003, Alereon's innovative products aim to simplify networking by facilitating wireless connections among personal computers, consumer electronics, and mobile devices, thereby eliminating the need for physical cables. The company’s offerings include the AL5100 RF transceiver, which integrates multiple sensitive components and supports a single-ended connection to antennas, and the AL5350 MAC/BBP, which combines digital and mixed signal circuitry for WiMedia UWB systems. Additionally, Alereon provides pre-built evaluation kits for demonstration and prototyping, Ethernet cable replacement kits, and wireless USB adapter kits. Its technology serves various applications across consumer electronics, medical sectors, and military and public safety domains.
Cameron Health
Series E in 2008
Cameron Health, Inc. is a development stage medical device company focused on creating innovative implantable electronic devices. With a team of experienced professionals, the company specializes in the development and manufacturing of subcutaneous implantable defibrillator (S-ICD) systems, designed for patients at risk of ventricular tachyarrhythmias. The S-ICD system includes key components such as the SQ-RX pulse generator, which delivers electrical pulses to manage cardiac arrhythmias, and the Q-TRAK subcutaneous electrode, implanted parallel to the left sternal border. Additionally, the Q-TECH programmer wirelessly communicates with the SQ-RX device, enhancing patient management. Cameron Health aims to provide advanced treatment options that were previously unattainable, leveraging state-of-the-art technologies to address complex medical challenges.
Intersect ENT
Series B in 2008
Intersect ENT, Inc. is a medical device company focused on developing innovative therapies for patients with ear, nose, and throat conditions. Founded in 2003 and headquartered in Menlo Park, California, the company specializes in drug delivery products aimed at enhancing treatment outcomes for chronic sinusitis and other related ailments. Its key offerings include the PROPEL and PROPEL mini drug-releasing implants, designed for patients undergoing sinus surgery, as well as the PROPEL Contour implant, which targets frontal and maxillary sinus ostia. Additionally, Intersect ENT provides SINUVA, a steroid-releasing implant intended for use in a physician office setting to address refractory disease. The company was previously known as Sinexus, Inc. before rebranding in 2009.
Cardiva Medical
Series D in 2008
Cardiva Medical, Inc. is a medical device company based in Santa Clara, California, specializing in innovative vascular access management products that facilitate the healing process following percutaneous catheterization procedures. Founded in 2002, the company develops and markets several key products, including the VASCADE VCS, an extravascular and bioabsorbable femoral access closure system that promotes rapid hemostasis while reducing complications for patients. Additionally, Cardiva offers the Cardiva CATALYST, a manual compression assistance device that enhances coagulation and provides temporary hemostasis. The company also manufactures the VASCADE MVP, designed for multi-site venous closure in electrophysiology procedures. Cardiva Medical primarily serves physicians and cardiac centers across the United States, focusing on transforming vascular closure to benefit patients and healthcare providers.
IDev Technologies
Series C in 2008
IDEV Technologies is an emerging growth medical device company that specializes in the development of innovative products for endovascular and interventional applications, particularly within interventional radiology, gastroenterology, vascular surgery, and cardiology. The company markets its flagship product, SUPERA, a self-expanding nitinol stent designed with a patented interwoven structure that enhances flexibility, radial strength, and resistance to kinking and crushing compared to competing stents. SUPERA is approved for treating biliary strictures in the United States and is currently undergoing clinical evaluation in the SUPERB IDE trial to assess its safety and efficacy for use in the superficial femoral artery.
Accumetrics
Series D in 2008
Accumetrics is a privately-held company based in San Diego, California, that specializes in the development, manufacturing, and marketing of the VerifyNow System, a suite of assays designed to assess platelet function. Founded in 1996, Accumetrics initially sold to Radiometer in 2000, but was repurchased by its management and investors in 2003. The VerifyNow System allows for the measurement of individual responses to various antiplatelet agents, providing critical diagnostic instrumentation and test kits that support clinicians in personalizing antiplatelet therapy for improved patient outcomes.
Asuragen, Inc. is a molecular diagnostics company based in Austin, Texas, specializing in oncology and genetic disorders. Founded in 2005, the company develops and commercializes a diverse array of diagnostic products and services aimed at improving patient management. Its offerings include various AmplideX reagents for detecting genetic markers, as well as comprehensive cancer diagnostic kits, such as QUANTIDEX and Signature assays that target specific mutations and gene fusions. Asuragen employs its patented Armored RNA technology in its diagnostics portfolio, which encompasses genetic and oncology testing products alongside industry-leading controls. The company also provides GLP testing services and operates a cGMP manufacturing facility, ensuring a seamless process from discovery to commercialization. With a focus on enhancing treatment outcomes through precise data, Asuragen plays a critical role in the medical community's efforts to improve patient care in oncology and genetics.
Apollo Endosurgery
Series A in 2007
Apollo Endosurgery, Inc. is a medical technology company based in Austin, Texas, specializing in the design, development, and commercialization of innovative medical devices for gastrointestinal health. Founded in 2005, the company focuses on advancing therapeutic endoscopy as a less invasive alternative to traditional surgical procedures, thereby reducing complication rates and overall healthcare costs. Its product portfolio includes the OverStitch and OverStitch Sx Endoscopic Suturing Systems, which enable physicians to place full-thickness sutures and secure tissue approximation through flexible endoscopy. Additionally, Apollo offers the X-Tack Endoscopic HeliX Tacking System and the Orbera Intragastric Balloon, which aids in weight management by reducing stomach capacity. The company's devices cater to gastroenterologists and bariatric surgeons, addressing various gastrointestinal conditions such as acute perforations and chronic fistulas. Apollo Endosurgery's commitment to innovation is rooted in the collaborative efforts of a distinguished group of gastroenterologists and surgeons who aimed to enhance the field of therapeutic endoscopy.
LDR Holding
Series C in 2007
LDR Holding Corporation is a medical device company specializing in the development and marketing of innovative implantable spine systems and instrumentation for surgical use. Founded in 2004 and headquartered in Austin, Texas, the company offers a diverse range of spinal surgery solutions, including cervical and lumbar artificial disc systems, pedicle screw systems, cervical cages, and synthetic bone substitutes, among others. LDR Holding's products are designed to address various spine disorders and are distributed through collaborations with surgeons and distributors in multiple countries, including Australia, Japan, and the United Kingdom. The company has expanded its global presence with additional offices in France, China, Brazil, and Germany, and it was formerly known as LDR Spine USA, Inc. prior to acquiring LDR Médical. LDR Holding is committed to advancing surgical technologies that enhance patient outcomes and support the surgeon community.
Alereon, Inc. is a fabless semiconductor company based in Austin, Texas, specializing in the development and marketing of ultra wideband (UWB) wireless chipsets. Founded in 2003, Alereon's innovative products aim to simplify networking by facilitating wireless connections among personal computers, consumer electronics, and mobile devices, thereby eliminating the need for physical cables. The company’s offerings include the AL5100 RF transceiver, which integrates multiple sensitive components and supports a single-ended connection to antennas, and the AL5350 MAC/BBP, which combines digital and mixed signal circuitry for WiMedia UWB systems. Additionally, Alereon provides pre-built evaluation kits for demonstration and prototyping, Ethernet cable replacement kits, and wireless USB adapter kits. Its technology serves various applications across consumer electronics, medical sectors, and military and public safety domains.
On-X Life Technologies
Venture Round in 2007
On-X Life Technologies Inc. is a company that specializes in the development, manufacture, and marketing of artificial heart valve replacement and repair products. The firm offers a diverse product portfolio that includes aortic and mitral heart valves with various sewing ring configurations, ascending aortic prostheses, and chordal repair products, among others. Additionally, On-X provides technical services related to carbon-based technology encompassing medical design, product development, and manufacturing. Founded in 1994 and headquartered in Austin, Texas, On-X Life Technologies aims to advance cardiovascular care through innovative medical devices. The company was formerly known as Medical Carbon Research Institute, L.L.C. and rebranded in June 2007.
BioSET
Venture Round in 2007
BioSET, Inc., founded in 2001 and based in Rockville, Maryland, specializes in the research and development of synthetic bioactive peptides aimed at enhancing bone and soft tissue repair. The company creates proprietary therapeutic peptides utilized as medical devices in orthobiologics applications. Its notable product, Amplex, is an implantable device that combines a peptide with a synthetic ceramic scaffold, designed for use in spinal fusion surgeries and other orthopedic procedures. Additionally, BioSET develops products for sports medicine and creates peptide signaling molecules along with various scaffold biomaterials for applications in trauma, fracture repair, and soft tissue treatments. As of February 2015, BioSET operates as a subsidiary of Ferring Pharmaceuticals Inc.
LDR Holding
Series B in 2006
LDR Holding Corporation is a medical device company specializing in the development and marketing of innovative implantable spine systems and instrumentation for surgical use. Founded in 2004 and headquartered in Austin, Texas, the company offers a diverse range of spinal surgery solutions, including cervical and lumbar artificial disc systems, pedicle screw systems, cervical cages, and synthetic bone substitutes, among others. LDR Holding's products are designed to address various spine disorders and are distributed through collaborations with surgeons and distributors in multiple countries, including Australia, Japan, and the United Kingdom. The company has expanded its global presence with additional offices in France, China, Brazil, and Germany, and it was formerly known as LDR Spine USA, Inc. prior to acquiring LDR Médical. LDR Holding is committed to advancing surgical technologies that enhance patient outcomes and support the surgeon community.
Crescent Biopharma
Series B in 2006
GlycoMimetics, Inc. is a clinical-stage biotechnology company dedicated to the discovery and development of innovative glycomimetic drugs aimed at addressing significant unmet medical needs associated with diseases influenced by carbohydrate biology. The company’s lead drug candidate, rivipansel, is a pan-selectin antagonist that has completed Phase III clinical trials for treating vaso-occlusive crises in sickle cell disease. Additionally, GlycoMimetics is developing uproleselan, an E-selectin inhibitor that is being tested in combination with chemotherapy for acute myeloid leukemia (AML) and in a Phase III trial for relapsed/refractory AML. The company also offers GMI-1359, which targets E-selectin and a chemokine receptor, having completed Phase I clinical trials, and is involved in developing other candidates, including GMI-1687 and Galectin-3. GlycoMimetics has established research collaborations, including an agreement with the National Cancer Institute and a partnership with Apollomics for the commercialization of uproleselan and GMI-1687. Founded in 2003, the company is headquartered in Rockville, Maryland.
Biomimetic Therapeutics
Series C in 2005
BioMimetic Therapeutics is a biotechnology company based in Franklin, Tennessee, founded in 1999. The company focuses on the development of biologically active drug-device combination products designed to stimulate the body's natural tissue regenerative processes. Its product portfolio includes Augment Injectable and Augment Rotator Cuff, which target various orthopedic and sports medicine conditions. These products are utilized for treating foot and ankle fusions, facilitating wrist fracture healing, and addressing surgical interventions for rotator cuff tears. Additionally, BioMimetic Therapeutics offers the Augment Tendinopathy Injection, aimed at managing injuries resulting from tendon overuse. The company is dedicated to advancing solutions for the healing of injuries and diseases affecting the skeleton and associated tissues.
Crescent Biopharma
Series A in 2004
GlycoMimetics, Inc. is a clinical-stage biotechnology company dedicated to the discovery and development of innovative glycomimetic drugs aimed at addressing significant unmet medical needs associated with diseases influenced by carbohydrate biology. The company’s lead drug candidate, rivipansel, is a pan-selectin antagonist that has completed Phase III clinical trials for treating vaso-occlusive crises in sickle cell disease. Additionally, GlycoMimetics is developing uproleselan, an E-selectin inhibitor that is being tested in combination with chemotherapy for acute myeloid leukemia (AML) and in a Phase III trial for relapsed/refractory AML. The company also offers GMI-1359, which targets E-selectin and a chemokine receptor, having completed Phase I clinical trials, and is involved in developing other candidates, including GMI-1687 and Galectin-3. GlycoMimetics has established research collaborations, including an agreement with the National Cancer Institute and a partnership with Apollomics for the commercialization of uproleselan and GMI-1687. Founded in 2003, the company is headquartered in Rockville, Maryland.
Alereon, Inc. is a fabless semiconductor company based in Austin, Texas, specializing in the development and marketing of ultra wideband (UWB) wireless chipsets. Founded in 2003, Alereon's innovative products aim to simplify networking by facilitating wireless connections among personal computers, consumer electronics, and mobile devices, thereby eliminating the need for physical cables. The company’s offerings include the AL5100 RF transceiver, which integrates multiple sensitive components and supports a single-ended connection to antennas, and the AL5350 MAC/BBP, which combines digital and mixed signal circuitry for WiMedia UWB systems. Additionally, Alereon provides pre-built evaluation kits for demonstration and prototyping, Ethernet cable replacement kits, and wireless USB adapter kits. Its technology serves various applications across consumer electronics, medical sectors, and military and public safety domains.